Claims for Patent: 8,871,745

Summary for Patent: 8,871,745

Title:	Proteasome inhibitors
Abstract:	The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Inventor(s):	Olhava; Edward J. (Newton, MA), Danca; Mihaela Diana (Mendham, NJ)
Assignee:	Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	13/964,708
Patent Claims:	1. A method of treating cancer, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or a boronic acid anhydride thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or a boronic acid anhydride thereof, and a pharmaceutically acceptable carrier: ##STR00009## with a second therapeutic agent, wherein: Ring A is selected from the group consisting of ##STR00010## Z.sup.1 and Z.sup.2 are each hydroxyl, alkoxy, aryloxy, or aralkoxy, or Z.sup.1 and Z.sup.2 together form a moiety derived from a boronic acid complexing agent; and wherein the cancer is multiple myeloma, lymphoma, or a recurrence of multiple myeloma or lymphoma. 2. The method of claim 1, wherein Ring A is ##STR00011## and Z.sup.1 and Z.sup.2 are each hydroxyl, or Z.sup.1 and Z.sup.2 together form a moiety derived from a boronic acid complexing agent. 3. The method of claim 2, wherein Z.sup.1 and Z.sup.2 are each hydroxyl. 4. The method of claim 1, wherein the compound of formula (I) is selected from the group consisting of: [(1R)-1-({[(2,3-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(5-chloro-2-fluorobenzoyl)amino]acetyl}amino)-3-methylbu- tyl]boronic acid; [(1R)-1-({[(3,5-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2,5-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; [(1R)-1-({[(2-bromobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boron- ic acid; [(1R)-1-({[(2-chloro-5-fluorobenzoyl)amino]acetyl}amino)-3-methyl- butyl]boronic acid; [(1R)-1-({[(4-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(3,4-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; [(1R)-1-({[(3-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; [(1R)-1-({[(3,4-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(3-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boron- ic acid; [(1R)-1-({[(2-chloro-4-fluorobenzoyl)amino]acetyl}amino)-3-methyl- butyl]boronic acid; [(1R)-1-({[(2,3-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boron- ic acid; [(1R)-1-({[(2,4-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl- ]boronic acid; [(1R)-1-({[(4-chloro-2-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]bo- ronic acid; [(1R)-1-({[(4-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; [(1R)-1-({[(2,4-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]b- oronic acid; and [(1R)-1-({[(3,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid. 5. The method as in any one of claims 1-3, wherein the cancer is multiple myeloma. 6. The method as in any one of claims 1-3, wherein the cancer is lymphoma. 7. The method as in any one of claims 1-3, wherein the patient in need of the treatment is a patient having or at risk of developing or experiencing a recurrence in a cancer selected from the group consisting of multiple myeloma and lymphoma. 8. The method as in any one of claims 1-3, wherein the second therapeutic agent is melphalan. 9. The method as in any one of claims 1-3, wherein the second therapeutic agent is lenalidomide. 10. The method as in any one of claims 1-3, wherein the compound or pharmaceutical composition is administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. 11. The method of claim 10, wherein the compound or composition is administered orally, intravenously, or subcutaneously. 12. The method of claim 10, wherein the compound or composition is administered systemically. 13. The method of claim 10, wherein the compound or composition is administered locally. 14. A method of treating cancer, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I), ##STR00012## or a pharmaceutically acceptable salt or a boronic acid anhydride thereof, with lenalidomide wherein: Ring A is ##STR00013## Z.sup.1 and Z.sup.2 are each hydroxyl, or Z.sup.1 and Z.sup.2 together form a moiety derived from a boronic acid complexing agent; and wherein the cancer is multiple myeloma, lymphoma, or a recurrence of multiple myeloma or lymphoma. 15. The method of claim 14, wherein Z.sup.1 and Z.sup.2 are each hydroxyl. 16. The method of claim 15, wherein Z.sup.1 and Z.sup.2 together form a moiety derived from a boronic acid complexing agent. 17. The method as in any one of claims 14-16, wherein the cancer is multiple myeloma. 18. The method as in any one of claims 14-16, wherein the cancer is lymphoma. 19. The method as in any one of claims 14-16, wherein the patient in need of the treatment is a patient having or at risk of developing or experiencing a recurrence in a cancer selected from the group consisting of multiple myeloma and lymphoma. 20. A method of treating cancer, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I), ##STR00014## or a pharmaceutically acceptable salt or a boronic acid anhydride thereof, with melphalan wherein: Ring A is ##STR00015## and Z.sup.1 and Z.sup.2 are each hydroxyl, or Z.sup.1 and Z.sup.2 together form a moiety derived from a boronic acid complexing agent. 21. The method of claim 20, wherein Z.sup.1 and Z.sup.2 are each hydroxyl. 22. The method of claim 20, wherein Z.sup.1 and Z.sup.2 together form a moiety derived from a boronic acid complexing agent. 23. The method as in any one of claims 20-22, wherein the cancer is multiple myeloma. 24. The method as in any one of claims 20-22, wherein the cancer is lymphoma. 25. The method as in any one of claims 20-22, wherein the patient in need of the treatment is a patient having or at risk of developing or experiencing a recurrence in a cancer selected from the group consisting of multiple myeloma and lymphoma.